Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigatio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback